Sciclone Pharmaceuticals (SCLN) 7.85 $SCLN
Correction: SciClone to Present at BIO CEO & Investor Conference on February 9, 2015 at 11 am ET
Marketwired - Wed Jan 28, 3:05PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 11:00 am ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City.
SCLN: 7.85 (+0.08)
SciClone to Present at BIO CEO & Investor Conference on February 9, 2015
Marketwired - Wed Jan 28, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 9:00 am ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City.
SCLN: 7.85 (+0.08)
Sciclone Pharmaceuticals Has Returned 36.7% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Wed Jan 21, 9:11AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 5 months, Sciclone Pharmaceuticals has returned 36.65% as of today's recent price of $7.42.
SCLN: 7.85 (+0.08)
Sciclone Pharmaceuticals Up 40.5% Since SmarTrend Uptrend Call (SCLN)
Comtex SmarTrend(R) - Tue Jan 13, 4:50PM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 5 months, Sciclone Pharmaceuticals has returned 40.52% as of today's recent price of $7.63.
SCLN: 7.85 (+0.08)
Technical Coverage on Pharma Stocks - Hospira, Auxilium Pharma, Medicines, SciClone Pharma, and Nektar Therapeutics
PR Newswire - Tue Jan 13, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Hospira Inc. (NYSE: HSP), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), The Medicines Company (NASDAQ: MDCO), SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, January 12, 2015, the NASDAQ Composite ended at 4,664.71, down 0.84%, the Dow Jones Industrial Average declined 0.54%, to finish the day at 17,640.84, and the S&P 500 closed at 2,028.26, down 0.81%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 812.68, down 0.07%, while the index has advanced 11.54% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 29.79 (+0.91), AUXL: 36.47 (-0.06), SCLN: 7.85 (+0.08), NKTR: 13.54 (-0.14), HSP: 87.35 (unch)
FDA clears Daiichi-Sankyo anticoagulant
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:55PM CST
PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), MDCO: 29.79 (+0.91), BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), SCLN: 7.85 (+0.08), MSLI: 1.96 (+0.08)
54.1% Return Seen to Date on SmarTrend Sciclone Pharmaceuticals Call (SCLN)
Comtex SmarTrend(R) - Tue Jan 06, 10:56AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 5 months, Sciclone Pharmaceuticals has returned 54.14% as of today's recent price of $8.37.
SCLN: 7.85 (+0.08)
SciClone affirms 2014 guidance and gives outlook for coming year
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 6:06AM CST
SCLN: 7.85 (+0.08)
SciClone Provides 2014 Financial Update and 2015 Revenue Guidance
Marketwired - Tue Jan 06, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reconfirmed its anticipated year-end 2014 revenue and non-GAAP earnings per share (EPS) guidance, and provided its anticipated revenue guidance for 2015, as follows.
SCLN: 7.85 (+0.08)
Shares of SCLN Up 63.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 30, 9:40AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 5 months, Sciclone Pharmaceuticals has returned 63.54% as of today's recent price of $8.88.
SCLN: 7.85 (+0.08)
Uptrend Call Working As Sciclone Pharmaceuticals Stock Rises 59.9% (SCLN)
Comtex SmarTrend(R) - Tue Dec 23, 9:09AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 4 months, Sciclone Pharmaceuticals has returned 59.85% as of today's recent price of $8.68.
SCLN: 7.85 (+0.08)
SciClone to promote two Medicines Company products in China
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:50AM CST
MDCO: 29.79 (+0.91), SCLN: 7.85 (+0.08)
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
Business Wire - Thu Dec 18, 6:00AM CST
The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focused on hospital care, and SciClone Pharmaceuticals (Nasdaq: SCLN), a U.S. based, China focused specialty pharmaceutical company, today announced the establishment of a strategic partnership for two cardiovascular products in China. The partnership includes an agreement granting SciClone a license and the exclusive rights in China to promote two products of The Medicines Company:
MDCO: 29.79 (+0.91), SCLN: 7.85 (+0.08)
Insider Trading Alert - JAZZ, ARE And SCLN Traded By Insiders
at The Street - Fri Dec 12, 10:30AM CST
Stocks with insider trader activity include JAZZ, ARE and SCLN
ARE: 94.90 (-1.29), JAZZ: 169.69 (+6.89), SCLN: 7.85 (+0.08)
Sciclone Pharmaceuticals Has Returned 61.4% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Mon Dec 08, 10:59AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 4 months, Sciclone Pharmaceuticals has returned 61.42% as of today's recent price of $8.77.
SCLN: 7.85 (+0.08)
Update: SciClone Pharmaceuticals Exceeds Earnings Estimates For Q3
David Zanoni - at Seeking Alpha - Sat Nov 15, 12:21AM CST
SCLN: 7.85 (+0.08)
Correction: SciClone to Present at BIO CEO & Investor Conference on February 9, 2015 at 11 am ET
Marketwired - Wed Jan 28, 3:05PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 11:00 am ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City.
SCLN: 7.85 (+0.08)
SciClone to Present at BIO CEO & Investor Conference on February 9, 2015
Marketwired - Wed Jan 28, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Friedhelm Blobel, Ph.D., Chief Executive Officer, will present a corporate overview and business update at the 17th Annual BIO CEO & Investor Conference at 9:00 am ET on Monday, February 9, 2015, at the Waldorf Astoria Hotel in New York City.
SCLN: 7.85 (+0.08)
Sciclone Pharmaceuticals Has Returned 36.7% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Wed Jan 21, 9:11AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 5 months, Sciclone Pharmaceuticals has returned 36.65% as of today's recent price of $7.42.
SCLN: 7.85 (+0.08)
Sciclone Pharmaceuticals Up 40.5% Since SmarTrend Uptrend Call (SCLN)
Comtex SmarTrend(R) - Tue Jan 13, 4:50PM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 5 months, Sciclone Pharmaceuticals has returned 40.52% as of today's recent price of $7.63.
SCLN: 7.85 (+0.08)
Technical Coverage on Pharma Stocks - Hospira, Auxilium Pharma, Medicines, SciClone Pharma, and Nektar Therapeutics
PR Newswire - Tue Jan 13, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Hospira Inc. (NYSE: HSP), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), The Medicines Company (NASDAQ: MDCO), SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), and Nektar Therapeutics (NASDAQ: NKTR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, January 12, 2015, the NASDAQ Composite ended at 4,664.71, down 0.84%, the Dow Jones Industrial Average declined 0.54%, to finish the day at 17,640.84, and the S&P 500 closed at 2,028.26, down 0.81%. The losses were broad based as nine out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 812.68, down 0.07%, while the index has advanced 11.54% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 29.79 (+0.91), AUXL: 36.47 (-0.06), SCLN: 7.85 (+0.08), NKTR: 13.54 (-0.14), HSP: 87.35 (unch)
FDA clears Daiichi-Sankyo anticoagulant
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:55PM CST
PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), MDCO: 29.79 (+0.91), BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), SCLN: 7.85 (+0.08), MSLI: 1.96 (+0.08)
54.1% Return Seen to Date on SmarTrend Sciclone Pharmaceuticals Call (SCLN)
Comtex SmarTrend(R) - Tue Jan 06, 10:56AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 5 months, Sciclone Pharmaceuticals has returned 54.14% as of today's recent price of $8.37.
SCLN: 7.85 (+0.08)
SciClone affirms 2014 guidance and gives outlook for coming year
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 6:06AM CST
SCLN: 7.85 (+0.08)
SciClone Provides 2014 Financial Update and 2015 Revenue Guidance
Marketwired - Tue Jan 06, 5:00AM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reconfirmed its anticipated year-end 2014 revenue and non-GAAP earnings per share (EPS) guidance, and provided its anticipated revenue guidance for 2015, as follows.
SCLN: 7.85 (+0.08)
Shares of SCLN Up 63.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 30, 9:40AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 5 months, Sciclone Pharmaceuticals has returned 63.54% as of today's recent price of $8.88.
SCLN: 7.85 (+0.08)
Uptrend Call Working As Sciclone Pharmaceuticals Stock Rises 59.9% (SCLN)
Comtex SmarTrend(R) - Tue Dec 23, 9:09AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 4 months, Sciclone Pharmaceuticals has returned 59.85% as of today's recent price of $8.68.
SCLN: 7.85 (+0.08)
SciClone to promote two Medicines Company products in China
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 8:50AM CST
MDCO: 29.79 (+0.91), SCLN: 7.85 (+0.08)
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
Business Wire - Thu Dec 18, 6:00AM CST
The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focused on hospital care, and SciClone Pharmaceuticals (Nasdaq: SCLN), a U.S. based, China focused specialty pharmaceutical company, today announced the establishment of a strategic partnership for two cardiovascular products in China. The partnership includes an agreement granting SciClone a license and the exclusive rights in China to promote two products of The Medicines Company:
MDCO: 29.79 (+0.91), SCLN: 7.85 (+0.08)
Insider Trading Alert - JAZZ, ARE And SCLN Traded By Insiders
at The Street - Fri Dec 12, 10:30AM CST
Stocks with insider trader activity include JAZZ, ARE and SCLN
ARE: 94.90 (-1.29), JAZZ: 169.69 (+6.89), SCLN: 7.85 (+0.08)
Sciclone Pharmaceuticals Has Returned 61.4% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Mon Dec 08, 10:59AM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on August 12th, 2014 at $5.43. In approximately 4 months, Sciclone Pharmaceuticals has returned 61.42% as of today's recent price of $8.77.
SCLN: 7.85 (+0.08)
Update: SciClone Pharmaceuticals Exceeds Earnings Estimates For Q3
David Zanoni - at Seeking Alpha - Sat Nov 15, 12:21AM CST
SCLN: 7.85 (+0.08)
